Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy

Official Title

A Randomized Phase II Trial to Assess the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy

Summary:

A randomized phase II trial to assess the efficacy and safety of selective metabolically adaptive radiation dose escalation in locally advanced non-small cell lung cancer receiving definitive chemoradiotherapy. Eligible and consenting patients will be randomized to receive conventional chemoradiotherapy or chemoradiotherapy with a radiation (RT) integrated boost. All patients will receive a fludeoxyglucose-positron emission tomography (FDG-PET) scan within two weeks prior to starting treatment. The primary outcome is to determine if dose escalation to metabolically active tumour subvolumes will reduce local-regional failure rate at 2 years.

Trial Description

Primary Outcome:

• Reduction of local-regional failure rate

• Progression-Free Survival
• Overall Survival
• Grade 3-5 Toxicity Rate
• Quality of Life FACT-L
• Quality of Life EQ-5D
• Dose-Response Characterization
• Dose Escalation Feasibility
• Imaging Use

View this trial on ClinicalTrials.gov